Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 27Melanoma 4Sarcoma 3Liposarcoma 3Ovarian Neoplasms 2Neoplasms 2Breast Cancer Metastatic 2Thymus Neoplasms 1Teratoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma 1Locoregional Recurrence 1Liposarcoma, Myxoid 1Lipoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2 Negative Breast Cancer 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Fulvestrant 5Letrozole 3Capecitabine 3ribociclib 2exemestane 2dalpiciclib 2apatinib 2Irinotecan 2Gemcitabine 2Anastrozole 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1palbociclib 1margetuximab 1irinotecan sucrosofate 1fluzoparib 1abemaciclib 1Vinorelbine 1Trastuzumab 1Tamoxifen 1Paclitaxel 1Liposomes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Cancer Metastatic × ribociclib × Clear all
NCT06849947 2025-12-24

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Samsung Medical Center

Phase 2 Not yet recruiting
272 enrolled
Breast

Breast Cancer Metastatic

NCT03555877 2023-07-07

AMICA

GBG Forschungs GmbH

Phase 2 Completed
56 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡